A chemotherapy nano-booster unlocks wider therapeutic window for prostate cancer treatment

Area of Science:

• Oncology
• Nanomedicine
• Natural Products Chemistry

Background:

• Clinical chemotherapy for prostate cancer faces challenges with high treatment thresholds and drug toxicity.
• Existing therapeutic strategies have limited progress in improving outcomes and reducing side effects.
• Broadening the chemotherapeutic window is crucial for advancing prostate cancer treatment.

Purpose of the Study:

• To investigate the synergistic effect of gossypol (GSP) and cabazitaxel (CTX) in prostate cancer.
• To develop a novel carrier-free nano-booster co-assembled from GSP and CTX.
• To evaluate the therapeutic potential of this nano-booster in preclinical prostate cancer models.

Main Methods:

• Molecular co-assembly of gossypol and cabazitaxel into a carrier-free nano-booster.
• In vitro assessment of enhanced chemosensitivity and drug tolerability.
• In vivo evaluation of the nano-booster's efficacy in mouse prostate tumor xenograft models.

Main Results:

• Gossypol significantly enhances cabazitaxel chemosensitivity, enabling ultra-low dose efficacy.
• The GSP-CTX nano-booster demonstrates improved maximum tolerable dose for cabazitaxel.
• Striking therapeutic benefits were observed in preclinical mouse models of prostate cancer.

Conclusions:

• Gossypol acts as a chemotherapeutic enhancer, unlocking an ultra-low-dose chemotherapeutic window.
• Precise dual-drug nanoassembly improves drug tolerability and therapeutic outcomes.
• This approach advances chemotherapeutic window expansion and self-sensitized chemotherapy for clinical application.